Orbis Medicines secures €90m to advance oral macrocycle drugs
Orbis Medicines secures €90m in Series A funding to accelerate the development of oral macrocycle drugs, leveraging automated chemistry and machine learning.
ADVERTISEMENT
About Michael Kuhrt
This author has not written his bio yet.
But we are proud to say that Michael Kuhrt contributed 541 entries already.
Entries by Michael Kuhrt
Revolutionising research
LAB Automation – The Society for Laboratory Automation and Screening (SLAS) is transforming the global life sciences community by uniting interdisciplinary researchers and technology providers to drive innovation in laboratory automation and research.
Breakthroughs honoured: 2024 Nobel Prizes
As part of the 2024 Nobel Prize Week, the prestigious awards have been presented. These include the Nobel Prize in Medicine or Physiology for the discoverers of microRNAs as a new class of regulatory molecules, and the Nobel Prize in Chemistry for AI-supported methods in protein design and the rapid calculation of their structures.
Dewpoint Therapeutics and Mitsubishi Tanabe partner on ALS therapy
Dewpoint Therapeutics Inc and Mitsubishi Tanabe Pharma Corporation have formed a collaboration, valued at up to $480m, to develop a novel small molecule condensate modulator for ALS, leveraging groundbreaking European research in condensate biology.
CN Bio launches PhysioMimix Bioavailability assay kit: Human 18
CN Bio, a leading provider of Organ-on-a-chip Systems and solutions that accelerate drug discovery and development workflows, today announced the launch of its PhysioMimix® Bioavailability assay kit: Human 18. Harnessing the capabilities of the PhysioMimix Multi-organ System, the kit enhances lead optimization and preclinical testing pipelines, providing an all-in-one solution to generate predictive insights into human oral bioavailability, and better inform lead candidate selection.
BioNsight® cloud – Your Data, Simply There
We live in an era of industrial transformation with the implementation of digital tools to handle increasing data amounts, as well as automation to facilitate workflows. Of course, this development does not stop at the bioprocess industry. Digital tools offer the possibility to enhance working efficiency and monitor your bioreactor culture without the need to be in the lab. Introducing BioNsight® cloud, a true cloud-based software solution for bioprocess monitoring and analysis, fully integrated into the Eppendorf bioprocess control software DASware® control 6.
Transforming research
The Society for Laboratory Automation and Screening (SLAS) is transforming the global life sciences community by uniting interdisciplinary researchers and technology providers to drive innovation in laboratory automation and research.
A promising semester for YEBN
The Young European Biotech Network (YEBN) is preparing for a busy semester, with a variety of events and initiatives planned through the end of 2024. From launching a new community platform to hosting key events, YEBN aims to support innovation, facilitate collaboration, and address the evolving needs of the biotech community.
Transgene and ProBioGen forge partnership
The Strasbourg-based biotech company Transgene and the Berlin-based CDMO ProBioGen have entered into a licensing agreement to collaboratively advance the development of individualised cancer vaccines.
Sustainable Ultra-Low Freezing with the U701V
Ultra-low freezers are playing a key role in biomedical research as they are required to store very temperature-sensitive biologicals such as DNA, enzymes and more, but they have high energy demands. Recognizing these issues, B Medical Systems has introduced the U701V, a new ULT freezer that balances energy efficiency with exceptional performance.